Tumors of the cornea and conjunctiva

Current Opinion in Ophthalmology

Volumn 7, Issue 4, 1996, Pages 28-34

  Spraul, Christoph W ^a   Grossniklaus, Hans E ^a  

^a EMORY EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AUTOGRAFT; CANCER RECURRENCE; CONJUNCTIVA TUMOR; CORNEA TUMOR; HUMAN; JUVENILE XANTHOGRANULOMA; MYXOMA; PRIORITY JOURNAL; PROGNOSIS; PTERYGIUM; REVIEW; SQUAMOUS CELL CARCINOMA; SQUAMOUS EPITHELIUM;

EID: 0029856771     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-199608000-00006     Document Type: Review

References (42)

1. Toshida H, Nakayasu K, Okisaka S, Kanai A: Incidence of tumors and tu• mor-like lesions in the conjunctiva and the cornea. J Jpn Ophthalmol Soc 1995, 99:186-189. These authors analyzed the incidence of tumor and tumor-like lesions of the conjunctiva and cornea during a 13-year period. There were 126 cases including 116 benign and 10 malignant lesions studied.
2. Lee GA, Hirst LW: Ocular surface squamous neoplasia. Surv Ophthal•• mol 1995, 39:429-450. This is an excellent article reviewing epidemiology, etiology, clinical findings, differential diagnosis, preoperative diagnostic tools, histopathology, and treatment modalities of OSSN, ie, dysplasia, carcinoma in situ, and invasive squamous cell carcinoma.
3. Dua HS, Gomes JAP, Donoso LA, Laibson PR: The ocular surface as • part of the mucosal immune system: conjunctival mucosa-specific lymphocytes in ocular surface pathology. Eye 1995, 9:261-267. These authors investigated three biopsy specimens from patients with conjunctival intraepithelial neoplasia using immunohistochemical methods for the presence of CD8, CD4, and human mucosal lymphocytes and compared the results with control patients. They found significant differences in the CD8/HTL ratio and the CD8/CD4 ratio between both groups.
4. Muccioli C, Belford R Jr, Burnier M, Rao N: Squamous cell carcinomas of the conjunctiva in a patient with the acquired immunodeficiency syndrome. Am J Ophthalmol 1995, 121:94-96.
5. Ateenyi-Agaba C: Conjunctival squamous-cell carcinoma associated with HIV infection in Kampala, Uganda. Lancet 1995, 345:695-696.
6. Goedert JJ, Coté TR: Conjunctival malignant disease with AIDS in USA. Lancet 1995, 346:257-258.
7. Ullman S, Augsburger JJ, Brady LW: Fractionated epibulbar 1-125 plaque radiotherapy for recurrent mucoepidermoid carcinoma of the bulbar conjunctiva. Am J Ophthalmol 1995, 119:102-103.
8. Eng AM, Rosner M: Conjunctival melanomas. Int J Dermatol 1995, • 34:349-353. The nomenclature and the clinical and pathologic features of cutaneous and conjunctival melanocytic lesions are reviewed. The difference between histologic features and classification of melanocytic lesions in these two locations are discussed.
9. McCartney AC: Pathology of ocular melanomas. Br Med Bull 1995, • 51:678-693. This article reviews the clinical and histopathologic features of ocular melanocytic lesions.
10. Carney JA: Carney complex: the complex of myxomas, spotty pigmen•• tation, endocrine overactivity, and schwannomas. Semin Dermatol 1995, 14:90-98. The author discusses in a comprehensive way the different clinical features of the Carney complex.
11. Jakobiec FA, Folberg R, Iwamoto T: Clinicopathologic characteristics of premalignant and malignant melanocytic lesions of the conjunctiva. Ophthalmology 1989, 96:147-166.
12. Gloor P, Alexandrakis G: Clinical characterization of primary acquired •• melanosis. Invest Ophthalmol Vis Sci 1995, 36:1721-1729. These authors examined 146 patients for the presence of PAM. The prevalence of PAM was determined and factors associated with PAM were investigated. They found a prevalence of 36% and concluded that transformation of PAM to conjunctival melanoma must be extremely rare. In addition, they found that the presence of PAM was associated with hypertension, cigarette smoking, and the absence of ocular surface disease.
13. Hungerford JL: Management of ocular melanoma. Br Med Bull 1995, • 51:694-716. This author reviews the pathogenesis and treatment modalities of ocular melanocytic lesions.
14. Horie Y, Ikawa S, Okamoto I, et al.: Myxoma of the conjunctiva: a case • report and a review of the literature. Jpn J Ophthalmol 1995, 39:77-82. These authors reviewed the literature of conjunctival myxoma and reported on an additional case.
15. de Gottrau P, Tamm S, Holbach LM, Naumann GOH: Conjunctival myxoma: apropos of an anatomo-clinical case. J Fr Ophtalmol 1995, 18:481-483.
16. Cameron JA, Mahmood MA: Pyogenic granulomas of the cornea. Oph• thalmology 1995, 102:1681-1687. These authors reported on 14 patients with histologically proven pyogenic granuloma of the cornea. The precipitating event was a persistent epithelial defect in nine patients. Treatment consisted of excisional biopsy and improvement of the underlying ocular surface disorders. Three patients had recurrent disease.
17. Spraul CW, Lang GE, Lang GK: Juvenile xanthogranuloma of the cor•• neoscleral limbus: report of a patient and review of the literature. Klin Monatsbl Augenheilkd 1995, 206:467-473. These authors reviewed the literature for all reported cases of juvenile xanthogranuloma involving the corneoscleral limbus and reported on another case. The age of onset in the group of limbal juvenile xanthogranuloma without intraocular disease is higher as compared with the group with intraocular involvement. Simple excision is often followed by recurrence. This recurrence should be treated with deeper excision and using a lamellar graft.
18. Tomidokoro A, Oshika T: Quantitative evaluation of corneal irregular astigmatism using computed corneal topography. Nippon Ganka Gakkai Zasshi 1995, 99:296-301.
19. Pavilack MA, Halpern BL: Corneal topography changes induced by pterygia. J Refract Corneal Surg 1995, 11:92-95.
20. loachim-Velogianni E, Tsironi E, Agnantis E, et al.: HLA-DR antigen ex• pression in pterygium epithelial cells and lymphocyte subpopulation: an immunohistochemical study. Ger J Ophthalmol 1995, 4:123-129. In this immunohistochemical study, the authors compared 35 surgically excised pterygia with seven samples of normal conjunctiva. HLA-DR antigen expression in epithelial cells, B cells, suppressor, and helper lymphocytes. Langerhans' cells, and monocytes and macrophages were investigated. Aberrant HLA-DR antigen expression in epithelial cells was detected in 86% of pterygia and in no control case study.
21. Butrus SI, Ashraf MF, Laby DM, et al.: Increased numbers of mast cells in pterygia. Am J Ophthalmol 1995, 119:236-237.
22. Karukonda SRK, Thompson HW, Beuerman RW, et al.: Cell cycle kinet•• ics in pterygium at three latitudes. Br J Ophthalmol 1995, 79:313-317. These authors evaluated the cell cycle kinetics of 93 specimens of pterygial tissue as well as 19 specimens of normal conjunctiva from patients at three different latitudes (1°, 22°, 34°) by flow cytometry. The results showed no difference in cellular proliferation pattern between pterygial and conjunctival tissue at any of the sites. However, the entire ocular surface proliferates more actively in regions closer to the equator.
23. Rohrbach IM, Starc S, Knorr M: Predicting recurrent pterygium based • on morphologic and immunohistologic parameters. Ophthalmologe 1995, 92:463-468. These authors compared histologic and immunohistologic parameters of excised pterygia which recurred to those which displayed no recurrence. Following parameters were studied: elastotic degeneration, amount of vascularization, loss of goblet cells, keratinization, reactive inflammation, amount of CD1a-, CD4-, CD8-and CD68-positive cells, expression of platelet-derived growth factor-α PDGFα PDGFβ platelet-derived growth factor-beta, epidermal growth, and laminin receptors. However, there was no difference in these parameters between both groups.
24. Lewallen S: A randomized trial of conjunctival autografting for pterygium in the tropics. Ophthalmology 1989, 96:1621-1614.
25. Jain S: Pterygium is a common ocular surface disorder for which medical treatment alone is not effective [letter]. Acta Ophthalmol Scand 1995, 73:191.
26. Cano-Parra J, Diaz-Llopis M, Maldonado MJ, et al.: Prospective trial of in•• traoperative mitomycin C in the treatment of primary pterygium. Br J Ophthalmol 1995, 79:439-441. In this prospective, randomized, double-blind, placebo controlled study, the effect of intraoperative mitomycin C (0.1 mg/mL) on the recurrence rate of excised pterygia was studied. The recurrence rate in the group of eyes with intraoperative application of mitomycin C was 3.3% and in the placebo group with intraoperative application of distilled water the rate was 38.8% (14/36). Neither serious ocular complication nor systemic toxicity were noted in the mitomycin C treated group.
27. Heiligenhaus A, Akova Y, Lung E, et al.: Pterygium excision with intra• operative administration of low dosage mitomycin C. Ophthalmologe 1995, 92:458-462. These authors investigated the effect of a single intraoperative instillation of mitomycin C (0.2 mg/mL) after pterygium excision on the recurrence rate. The recurrence rate was 22. 2% and the postoperative complications consisted of delayed conjunctival healing and granuloma formation in two cases.
28. Rachmiel R, Leiba H, Levartovsky SI: Results of treatment with topical • mitomycin C 0.02% following excision of primary pterygium. Br J Ophthalmol 1995, 79:233-236. These authors studied the effectiveness of instillation of mitomycin C eyedrops (0.02 mg/mL, twice daily for 5 days) after simple excision of the pterygium on the recurrence rate. The recurrence rate was 2.6% and encounter side effects were avascularized sciera (34%), ocular discomfort and lacrimation (13%), superficial punctate keratitis (8%), and pyogenic granuloma (5%).
29. Chen PP, Ariyasu RG, Kaza V, et al.: A randomized trial comparing mit•• omycin C and conjunctival autograft after excision of primary pterygium. Am J Ophthalmol 1995, 120:151-160. These authors performed a prospective, double-masked clinical trial of 64 patients (60 Hispanic) with pterygium. The patients were randomly assigned to three different treatment groups. In all groups excision of the pterygium was performed. This procedure was followed either by postoperative mitomycin C treatment (0.2 mg/mL, twice daily for 5 days), placebo (balanced saline solution), or conjunctival autograft. The recurrence rate after mitomycin C, conjunctival auto-graft, and placebo was 38%, 39%, and 88% of eyes, respectively.
30. Maldonado MJ, Cano-Parra J, Navea-Tejerina A, et al.: Inefficacy of low-dose intraoperative fluorouracil in the treatment of primary pterygium. Arch Ophthalmol 1995, 113:1356-1357.
31. Forster W, Atzler U, Ratkay I, Busse H: Excimer laser phototherapeutic • keratectomy (PTK) and modified bare sciera technique for treatment of pterygium. Ophthalmologe 1995, 92:424-426. These authors used a modified "bare sclera" technique for the treatment of 46 pterygia and smoothed the corneal surface with an excimer laser using the immersion method. A high recurrence rate (50% to 100%) depending on the length of the corneal involvement was noted.
32. Margo CE, Grossniklaus HE: Intraepithelial sebaceous neoplasia with•• out underlying invasive carcinoma. Surv Ophthalmol 1995, 39:293-301. These authors reported on two patients with intraepithelial sebaceous neoplasia without underlying invasive carcinoma. They discuss the histopathology and the histologic differential diagnosis. The pathogenesis of this lesions is unclear as is the biologic behavior. Diagnostic evaluations and treatment modalities are discussed.
33. Kurumety UR, Lustbader JM: Kaposi's sarcoma of the bulbar conjunctiva as an initial clinical manifestation of acquired immunodeficiency syndrome [letter]. Arch Ophthalmol 1995, 113:978.
34. Ferry AP, Font RL: Carcinoma metastatic to the eye and orbit: a clinicopathologic study of 227 cases. Arch Ophthalmol 1974, 92:276-286.
35. Ortiz JM, Esterman B, Paulson J: Uterine cervical carcinoma metastasis to subconjunctival tissue. Arch Ophthalmol 1995, 113:1362-1363.
36. Schworm HD, Boergen KP, Stefani FH: The initial clinical manifestation of rhabdomyosarcoma. Ophthalmologe 1995, 92:362-365.
37. Shields JA, Eagle RC, Shields CL, et al.: Orbital varix presenting as a subconjunctival mass. Ophthal Plast Reconstr Surg 1995, 11:37-38.
38. Weisenthal RW, Streeten BW, Dubansky AS, et al.: Burkitt lymphoma presenting as a conjunctival mass. Ophthalmology 1995, 102:129-134.
39. Chazerain P, Meyer O, Kaplan G, et al.: Ocular adnexa malignant lymphomas in Sjögren's syndrome: a report of 4 cases. Ann Med Interne (Paris) 1995, 146:223-225.
40. Archer KF, Hurwitz JJ, Heathcote G: Orbital angiolymphoid hyperplasia with eosinophilia. Presenting as chalazion. Ophthal Plast Reconstr Surg 1991, 7:208-221.
41. Kung ITM, Gibson JB, Bannatyne PM: Kimura's disease: a clinico-pathologic study of cases and its distinction from angiolymphoid hyperplasia with eosinophilia. Pathology 1984, 16:39-44.
42. Jayamanne DGR, Webber SK, Ridley REW, et al.: Angiolymphoid hyperplasia with eosinophilia (Kimura's disease) of the conjunctiva. Br J Ophthalmol 1995, 79:1053-1054.